Reimbursed Care Access in Ireland

Currently classified as a strictly controlled substance under Ireland's Misuse of Drugs legislation and designated within the schedules to the Misuse of Drugs Regulations (2017) and subsequent statutory instruments; possession, supply and manufacture are unlawful except where licensed for research or other specified purposes (including clinical trials). The Minister for Health has confirmed psilocin/psilocybin are Schedule 1 and that possession for research/forensic/industrial purposes may be permitted under licence (SI and Oireachtas written answer). # #

Currently classified as a controlled/illicit drug under the Misuse of Drugs Act and associated Regulations; there is no routine authorised medical use or reimbursement for MDMA outside of licensed clinical research. Access for medical use would require Ministerial licence/HPRA authorisation and trial approval; otherwise possession and supply are criminal offences. # #

Esketamine (Spravato®) is authorised in Ireland (EU/EEA marketing authorisation via EMA) for use in adults with treatment‑resistant major depressive disorder in combination with an SSRI or SNRI and there are specific risk‑mitigation and supervised‑use requirements in the product licence and SPC (administration in a clinic under supervision). # #

Health-technology assessment and reimbursement: the Irish National Centre for Pharmacoeconomics (NCPE) completed assessments of esketamine (HTA ID: 19055), and public documentation notes that following assessment and confidential price negotiations esketamine was approved for reimbursement in Ireland (HSE) in early 2022. Access within the public system is therefore possible under HSE/Hospital arrangements for patients meeting the licensed indication (treatment‑resistant depression) and under the product's supervised‑use conditions. # #

Reimbursement and delivery details: Spravato must be administered under direct supervision in a clinical setting because of blood‑pressure and dissociative effects; the authorised SPC and HPRA materials set out the special prescription and monitoring requirements. Reimbursement is determined via the NCPE/HSE process and individual hospital/practice-level arrangements; as is typical, patients are assessed by psychiatrists, must meet the licensed criteria (e.g., failure of at least two prior antidepressant treatments in the current episode / TRD), and treatment is delivered in specialist psychiatric services or designated clinics with the capacity for monitoring and post‑dose observation. # #

Ketamine is a licensed anaesthetic and controlled drug in Ireland and therefore legally available for legitimate medical uses (anaesthesia, pain management) under standard medicinal regulations; it is also listed among commonly controlled substances in public guidance. #

Off‑label psychiatric use: clinicians in Ireland prescribe ketamine off‑label for depressive disorders (including some treatment‑resistant cases) using sub‑anaesthetic intravenous or other dosing regimens. This use is off‑label (regulatory approval is for anaesthesia) and, in practice, ketamine treatments for depression in Ireland are most commonly provided by private clinics or specialist services rather than through routine HSE‑funded community mental health pathways; patients typically self‑fund or pay privately for infusion courses. (Examples of private clinic cost summaries and reporting on off‑label provision exist in public sources describing private ketamine services and associated patient costs.) # #

Research context and safety oversight: use of ketamine for depression in Ireland is the subject of clinical research and debate; where used off‑label clinicians are expected to follow professional guidance, obtain informed consent and ensure monitoring for adverse effects. There is limited/no routine public reimbursement for ketamine infusion therapy for depression, so access commonly depends on private provision or recruitment into clinical trials.

Currently classified as a strictly controlled substance under Ireland's Misuse of Drugs legislation (listed in schedules, making production, supply and possession unlawful except under licence for research or other permitted purposes). There is no authorised medical or reimbursed use outside of approved clinical research. # #

Currently classified under Ireland's controlled‑drugs regime; no authorised medical use or public reimbursement—access only via licensed research/clinical trials or specific Ministerial/HPRA licences. #

Currently controlled under Ireland's Misuse of Drugs statutory framework with no authorised medical use or reimbursement; any clinical use would require a licence and formal research approvals. Access outside licensed research is unlawful. #

Preparations containing DMT (including traditional ayahuasca brews) fall within the controlled substances regime; possession, importation and supply are prohibited except under licence for research/forensic/industrial purposes. There is no authorised or reimbursed medical use in routine practice. # #

Mescaline is listed among controlled substances under Ireland's drug scheduling and is not authorised for medical use or reimbursed—access is limited to licensed research or special authorised purposes. # #

Members of the 2C family (e.g., 2C‑B and related 2C‑X compounds) are captured by Ireland's controlled‑substance regulations and treated as illegal outside licensed research; there is no authorised medical or reimbursed access. # #